Arthur M. Cohen & Associates LLC purchased a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 3,990 shares of the biopharmaceutical company’s stock, valued at approximately $202,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. First Personal Financial Services raised its holdings in Bristol-Myers Squibb by 7.7% during the third quarter. First Personal Financial Services now owns 2,831 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 202 shares in the last quarter. Thomasville National Bank increased its holdings in shares of Bristol-Myers Squibb by 1.1% in the third quarter. Thomasville National Bank now owns 18,815 shares of the biopharmaceutical company’s stock valued at $954,000 after buying an additional 210 shares in the last quarter. Taylor Cottrill Erickson & Associates Inc. increased its holdings in shares of Bristol-Myers Squibb by 2.4% in the third quarter. Taylor Cottrill Erickson & Associates Inc. now owns 9,555 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 220 shares in the last quarter. Rehmann Capital Advisory Group increased its holdings in shares of Bristol-Myers Squibb by 2.2% in the second quarter. Rehmann Capital Advisory Group now owns 10,209 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 224 shares in the last quarter. Finally, Sunbelt Securities Inc. increased its holdings in shares of Bristol-Myers Squibb by 4.4% in the second quarter. Sunbelt Securities Inc. now owns 5,830 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 246 shares in the last quarter. 80.40% of the stock is currently owned by institutional investors.

In other Bristol-Myers Squibb news, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total transaction of $849,900.00. Following the transaction, the senior vice president now directly owns 74,471 shares in the company, valued at approximately $4,219,526.86. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Louis S. Schmukler sold 25,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the transaction, the insider now owns 31,963 shares in the company, valued at $1,807,827.28. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.

NYSE BMY opened at $58.02 on Friday. Bristol-Myers Squibb Co has a twelve month low of $42.48 and a twelve month high of $58.46. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The stock has a market cap of $91.88 billion, a price-to-earnings ratio of 14.58, a PEG ratio of 1.31 and a beta of 0.71. The firm’s 50 day moving average price is $52.90 and its two-hundred day moving average price is $48.19.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.06 by $0.11. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The firm had revenue of $6.01 billion for the quarter, compared to analysts’ expectations of $5.89 billion. During the same period in the previous year, the company posted $1.09 EPS. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. On average, research analysts forecast that Bristol-Myers Squibb Co will post 4.33 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Friday, October 4th were given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 2.83%. The ex-dividend date was Thursday, October 3rd. Bristol-Myers Squibb’s payout ratio is 41.21%.

Several research analysts have issued reports on BMY shares. Atlantic Securities raised Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a report on Wednesday, August 14th. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a report on Wednesday, September 18th. Bank of America started coverage on Bristol-Myers Squibb in a report on Wednesday, October 16th. They issued a “buy” rating and a $60.00 price target on the stock. Peel Hunt reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Tuesday, October 29th. Finally, ValuEngine cut Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $56.64.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Correction

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.